Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Mediators Inflamm

Retrieve available abstracts of 22 articles:
HTML format
Text format



Single Articles


    January 2019
  1. NING L, Lou X, Zhang F, Xu G, et al
    Nuclear Receptors in the Pathogenesis and Management of Inflammatory Bowel Disease.
    Mediators Inflamm. 2019;2019:2624941.
    PubMed     Text format     Abstract available


  2. ZHAO X, Li L, Li X, Li J, et al
    The Relationship between Serum Bilirubin and Inflammatory Bowel Disease.
    Mediators Inflamm. 2019;2019:5256460.
    PubMed     Text format     Abstract available


  3. HAN L, Wang XM, Di S, Gao ZZ, et al
    Innate Lymphoid Cells: A Link between the Nervous System and Microbiota in Intestinal Networks.
    Mediators Inflamm. 2019;2019:1978094.
    PubMed     Text format     Abstract available


  4. LI J, Zhao X, Li X, Lu M, et al
    Systematic Review with Meta-Analysis: Fecal Calprotectin as a Surrogate Marker for Predicting Relapse in Adults with Ulcerative Colitis.
    Mediators Inflamm. 2019;2019:2136501.
    PubMed     Text format     Abstract available


    January 2018
  5. GRZYBOWSKA-CHLEBOWCZYK U, Wysocka-Wojakiewicz P, Jasielska M, Cukrowska B, et al
    Oxidative and Antioxidative Stress Status in Children with Inflammatory Bowel Disease as a Result of a Chronic Inflammatory Process.
    Mediators Inflamm. 2018;2018:4120973.
    PubMed     Text format     Abstract available


  6. BOROS E, Kellermayer Z, Balogh P, Strifler G, et al
    Elevated Expression of AXL May Contribute to the Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease Patients.
    Mediators Inflamm. 2018;2018:3241406.
    PubMed     Text format     Abstract available


  7. TOLEDO-MAURINO JJ, Furuzawa-Carballeda J, Villeda-Ramirez MA, Fonseca-Camarillo G, et al
    The Transient Receptor Potential Vanilloid 1 Is Associated with Active Inflammation in Ulcerative Colitis.
    Mediators Inflamm. 2018;2018:6570371.
    PubMed     Text format     Abstract available


  8. CHARPENTIER C, Chan R, Salameh E, Mbodji K, et al
    Dietary n-3 PUFA May Attenuate Experimental Colitis.
    Mediators Inflamm. 2018;2018:8430614.
    PubMed     Text format     Abstract available


  9. DIGE A, Magnusson MK, Uhrenholt C, Rasmussen TK, et al
    Effects of Anti-TNFalpha Treatment on Mucosal Expression of IL-17A, IL-21, and IL-22 and Cytokine-Producing T Cell Subsets in Crohn's Disease.
    Mediators Inflamm. 2018;2018:3279607.
    PubMed     Text format     Abstract available


  10. LENNON EM, Borst LB, Edwards LL, Moeser AJ, et al
    Mast Cells Exert Anti-Inflammatory Effects in an IL10(-/-) Model of Spontaneous Colitis.
    Mediators Inflamm. 2018;2018:7817360.
    PubMed     Text format     Abstract available


  11. ZHANG C, Shu W, Zhou G, Lin J, et al
    Anti-TNF-alpha Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease.
    Mediators Inflamm. 2018;2018:3021863.
    PubMed     Text format     Abstract available


  12. OZ HS, Yeh SL, Amedei A
    Gut Inflammatory Diseases, Infection, and Nutrition.
    Mediators Inflamm. 2018;2018:7160859.
    PubMed     Text format    


    January 2017
  13. RAFA H, Benkhelifa S, AitYounes S, Saoula H, et al
    All-Trans Retinoic Acid Modulates TLR4/NF-kappaB Signaling Pathway Targeting TNF-alpha and Nitric Oxide Synthase 2 Expression in Colonic Mucosa during Ulcerative Colitis and Colitis Associated Cancer.
    Mediators Inflamm. 2017;2017:7353252.
    PubMed     Text format     Abstract available


  14. BAO X, Feng Z, Yao J, Li T, et al
    Roles of Dietary Amino Acids and Their Metabolites in Pathogenesis of Inflammatory Bowel Disease.
    Mediators Inflamm. 2017;2017:6869259.
    PubMed     Text format     Abstract available


  15. GUAN Q, Zhang J
    Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease.
    Mediators Inflamm. 2017;2017:4810258.
    PubMed     Text format     Abstract available


  16. DUVOISIN G, Lopez RN, Day AS, Lemberg DA, et al
    Novel Biomarkers and the Future Potential of Biomarkers in Inflammatory Bowel Disease.
    Mediators Inflamm. 2017;2017:1936315.
    PubMed     Text format     Abstract available


  17. CORETTI L, Natale A, Cuomo M, Florio E, et al
    The Interplay between Defensins and Microbiota in Crohn's Disease.
    Mediators Inflamm. 2017;2017:8392523.
    PubMed     Text format     Abstract available


    January 2016
  18. RODRIGUEZ-CANALES M, Jimenez-Rivas R, Canales-Martinez MM, Garcia-Lopez AJ, et al
    Protective Effect of Amphipterygium adstringens Extract on Dextran Sulphate Sodium-Induced Ulcerative Colitis in Mice.
    Mediators Inflamm. 2016;2016:8543561.
    PubMed     Text format     Abstract available


  19. BRYAN PF, Karla C, Edgar Alejandro MT, Sara Elva EP, et al
    Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel Disease.
    Mediators Inflamm. 2016;2016:9890141.
    PubMed     Text format     Abstract available


  20. ZHOU G, Yu L, Yang W, Wu W, et al
    Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease.
    Mediators Inflamm. 2016;2016:2543070.
    PubMed     Text format     Abstract available


  21. PHILLIPS-FARFAN B, Carvajal K, Medina-Torres EA, Espinosa-Padilla SE, et al
    Corrigendum to "Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel Disease".
    Mediators Inflamm. 2016;2016:7267956.
    PubMed     Text format     Abstract available


  22. KHAWAR MB, Abbasi MH, Sheikh N
    IL-32: A Novel Pluripotent Inflammatory Interleukin, towards Gastric Inflammation, Gastric Cancer, and Chronic Rhino Sinusitis.
    Mediators Inflamm. 2016;2016:8413768.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: